PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-1.68%
Cash & equivalents declining -1.68% while Medical - Pharmaceuticals shows -3.17% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-1.68%
Below half the Medical - Pharmaceuticals median of -5.00% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
3.30%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
0.78%
Inventory growth near Medical - Pharmaceuticals median of 0.88%. Charlie Munger sees standard industry practice. Check for normal demand patterns.
38.26%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.88%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
1.35%
Below half the Medical - Pharmaceuticals median of -1.55%. Jim Chanos would question if the company faces working capital strain.
2.18%
PP&E growth below half of Medical - Pharmaceuticals median of -0.95%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
-4.63%
Above 1.5x Medical - Pharmaceuticals median of -1.10%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-4.63%
Exceeding 1.5x Medical - Pharmaceuticals median of -0.76%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
1.21%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
-100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
12.54%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
1.85%
Below half the Medical - Pharmaceuticals median of -0.92%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
1.69%
Below half the Medical - Pharmaceuticals median of -1.18%. Jim Chanos might see potential stagnation or distress vs. peers.
1.19%
Payables growth near Medical - Pharmaceuticals median of 1.30%. Charlie Munger sees typical AP usage aligned with industry norms.
-0.55%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
731.80%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a robust subscription base vs. peers.
101.70%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
1.69%
Above 1.5x Medical - Pharmaceuticals median of 0.36%. Jim Chanos suspects potential working capital strain.
-4.79%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
-100.00%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential shortage of multi-year commitments.
-100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
101.81%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-4.09%
Above 1.5x Medical - Pharmaceuticals median of -2.28%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
0.93%
Below half Medical - Pharmaceuticals median of -1.46%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
2.59%
Below half Medical - Pharmaceuticals median of -1.10%. Jim Chanos suspects poor profitability or large dividend drains.
-1.96%
AOCI growth below half of Medical - Pharmaceuticals median -4.42%. Joel Greenblatt sees fewer exposures vs. peers.
-50.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
2.49%
Below half Medical - Pharmaceuticals median of -0.19%. Jim Chanos suspects slower net worth growth or losses vs. peers.
1.69%
Below half Medical - Pharmaceuticals median of -1.22%. Jim Chanos suspects a major slowdown or distress.
1.21%
Below half Medical - Pharmaceuticals median of -1.20%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
-21.26%
Above 1.5x Medical - Pharmaceuticals median of -0.32%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-34.88%
Below half of Medical - Pharmaceuticals median 5.02%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.